Review highlights the effectiveness and clinical implications of potassium-competitive acid blockers in acid suppression.
Potassium-competitive acid blockers (P-CABs) are a new class of acid-suppressing drugs; to date, only one of them (vonoprazan) has been approved for use in the United States. The authors of this article review how P-CABs (and vonoprazan in particular) differ from proton pump inhibitors (PPIs), evidence supporting their effectiveness, indications for vonoprazan, and ongoing and future studies.
No takes yet. Share an insight, caveat, or question.
Wehbe et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: